The growth of the extracorporeal membrane oxygenation (ECMO) system market can be contributed to the growing cardiovascular and respiratory diseases, rising adoption of ECMO as a bridge to lung transplantation, growing number of ECMO centers, conferences & training programs to increase awareness, and technological advancements. In addition, the rising geriatric population and the number of people suffering from diseases in populous countries such as India & China are factors that are expected to offer significant growth opportunities for ECMO systems.
However, complications associated with extracorporeal membrane oxygenation machine such as bleeding, infections, and technical failures; along with high cost and lack of skilled professionals is a challenge to the market.
Key Market Trends Respiratory Applications is expected to Dominate the Market
Asthma is one of the major noncommunicable diseases. It is a chronic disease of the air passages of the lungs which inflames and narrows them. According to a World Health Organization 2017 report, there are approximately 235 million people suffering from asthma globally. As per this report, there were 383,000 deaths due to asthma in 2015. Moreover, the prevalence of asthma seems to be increasing at a rapid pace.
As per the Center for Disease Control and Prevention (CDC) 2016 report, the prevalence of asthma among adults aged 20 and over increased from 7.1% in 2009-2010 to 9.2% in 2013-2014. Therefore ECMO is useful as to provide adequate gas exchange and prevent lung injury induced by mechanical ventilation. This is very helpful for asthama patients.
As a result, the use of ECMO in cases of near-fatal asthma (NFA) has increased over the years, as per a report by Hye Ju Yeo et al., published in Critical care Journal 2017. Hence all these factors are expected to help the market growth.
North America is Expected to Dominate the Market
As per the American heart association, coronary heart disease is the leading cause of deaths (45.1%) attributable to the cardiovascular disease in the United States, followed by stroke (16.5 %) and heart failure (8.5 %). Moreover, about 5.7 million adults in the United States die of heart failure every year, of which the percentage of in-hospital failures holds a huge potential to be reduced by the usage of ECMO. COPD is the third-leading cause of death in the United States, with its prevalence increasing in direct correlation with changing demography. Although, non-invasive mechanical ventilation (NIV) is the primary prognosis, a shift has been observed, in recent years, toward ECMO (which is considered to be a more efficient alternative).
According to a recent article published in 2018, the use of extracorporeal membrane oxygenation (ECMO) has been exponentially increasing over the last decade and is now considered as a mainstream lifesaving treatment modality in critical care medicine.
Hence, the survival rates for adults with severe acute respiratory failure treated with ECMO have also improved dramatically over the past 30 years. These factors are expected to help the market grow in the region.
Competitive Landscape Majority of the extra corporeal membrane oxygenation system are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
573 pages •
By Global Industry Analysts
• Apr 2021
- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Step by step: An aging US population and a rising prevalence of diabetes are expected to boost industry demand Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and the...
Health Care Provider
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.